Trial Profile
Clinical study of apatinib mesylate combined with paclitaxel in second-line and second-line maintenance therapy for advanced gastric cancer - open, single-arm exploratory study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2018
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Rivoceranib (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 20 Jul 2018 New trial record